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Abstract
Introduction: The long-term attributable burden related to acute respiratory distress syndrome (ARDS) is not fully
investigated. The aim of this study is to evaluate the quality of life (QOL) and functional status at 6 months after
hospitalization in patients at risk for ARDS who did and did not develop the syndrome.
Method: This is a population-based prospective cohort study of adult patients from Olmsted County, Minnesota,
with or at risk for ARDS hospitalized from October 2008 to July 2011. The primary outcomes were changes in QOL
and functional status, measured through 12-Item Short Form Survey (SF-12) and Barthel Index (BI) respectively, from
baseline to 6 months, compared between survivors who did and did not develop ARDS.
Results: Of 410 patients with or at risk for ARDS, 98 had baseline surveys collected and 67 responded to a 6-month
survey (26 ARDS, 41 non-ARDS). Both ARDS and non-ARDS groups had lower physical component of SF-12 at
baseline compared to general population (P < 0.001 for both). ARDS patients had poorer baseline functional status
compared to non-ARDS (mean BI 80 ± 25 vs. 88 ± 22, P = 0.03). No significant differences were observed for the
change between 6 months and baseline BI (delta 2.3 for ARDS vs. 2.0 for non-ARDS, P = 0.5), or mental (delta 2.7 vs. 2.4,
P = 0.9) or physical (delta –3 vs. –3.3, P = 0.9) component of SF-12 between survivors with and without ARDS.
Conclusion: In this population-based study, decreased QOL and functional status 6 months after hospitalization were
largely explained by baseline condition, with similar recovery in survivors who did and did not develop ARDS.
Introduction
Acute respiratory distress syndrome (ARDS) commonly
complicates acute illness in the intensive care unit (ICU).
This syndrome is associated with high morbidity and
mortality and tremendous costs [1]. With advances in
treatment and supportive measures [2, 3], an increasing
number of patients are surviving the syndrome with
remarkable lung recovery. However, outcome studies
show that many ARDS survivors develop long-term
neurocognitive, neuropsychological, neuromuscular, func-
tional and quality of life (QOL) impairment [4–13].
While many studies show both short- and long-term
decrease in QOL among ARDS survivors when com-
pared to the sex- and age-matched general population
[6, 8–10], the amount of decline directly attributable to
ARDS remains unclear. For the purpose of prioritizing
future prevention strategies, it is imperative to study the
attributed burden of this condition by quantifying spe-
cific patient-centered outcomes. In addition, data on
long-term QOL and functional status of ARDS survivors
has traditionally come from a secondary analysis of
selected clinical trial populations, which may involve
selection bias, as a very small proportion of eligible
patients are usually enrolled in randomized clinical trials.
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Additionally, there are limited data on long-term out-
comes of ARDS survivors with the assessment of their
pre-morbid condition [12, 14].
To evaluate the attributed burden of ARDS we evalu-
ated the QOL and functional status at 6 months post
hospitalization compared to baseline in a population-
based cohort of patients with ARDS, or at high risk of
ARDS.
Methods
This is a prospective, population-based cohort study. It
was approved by the Mayo Clinic Institutional Review
Board (IRB # 08-003560) and informed consent was
obtained from all eligible patients.
Study population
The study protocol has been published previously [15].
Eligible patients included adult residents from Olmsted
County, Minnesota, who were admitted to the Mayo
Clinic between October 2008 and July 2011 with one or
more ARDS predisposing conditions (sepsis, pneumonia,
aspiration, pancreatitis, shock, high-risk trauma, and
high-risk surgery) within 6 hours of hospital admission
[16]. We excluded the following patients: those admitted
for cardiac telemetry, coronary care, low-risk elective
surgeries, or labor and delivery; patients age <18 years;
patients who were treated for comfort care or hospice
care only; patients who had ARDS or pulmonary edema
at the time of hospital admission; patients readmitted to
the hospital; patients transferred from other hospitals;
and patients who denied research authorization.
Identification of patients at risk of developing ARDS
To identify patients at risk of developing ARDS for in-
clusion in the study, we used a previously validated acute
lung injury (ALI) prediction model: the lung injury pre-
diction score (LIPS) [17]. The LIPS model incorporates
demographic, environmental, and clinical characteristics
at the time of hospital admission to identify patients at
high risk of ARDS [16].
Ascertainment of development of ARDS
Screening for ARDS development was performed by pre-
viously validated electronic surveillance (ARDS “sniffer”)
[18]. The electronic alert is triggered by the following
combination of observations: 1) qualifying arterial blood
gas analysis: the ratio of partial pressure of oxygen to
inspired oxygen concentration (PaO2/FIO2) <200 and 2)
qualifying chest radiograph report (free-text Boolean
query containing trigger words: “bilateral” and “infil-
trate” or “edema”). The ARDS sniffer demonstrated
excellent negative predictive value at the time of hospital
admission [18]. Trained investigators subsequently
reviewed all ARDS sniffer alerts and confirmed the
presence or absence of ARDS according to the standard
definition based on the American-European consensus
conference [19]. This process showed excellent inter-rater
reliability [20].
Severity of illness and comorbidities
Charlson comorbidity index at the time of hospital
admission was calculated in all patients. APACHE III
scores were calculated at the time of ICU admission.
Quality of life and functional status
QOL was assessed using the 12-Item Short Form Survey
(SF-12), which is a validated tool developed to replicate
the 36-Item Short Form Survey (SF-36) and minimize
respondent burden [21, 22]. Functional status was as-
sessed using the Barthel Index (BI), one of the best meas-
urement scales for activities of daily living, previously used
in ICU survivors [23, 24]. These surveys were adminis-
tered by trained study coordinators [21]. Assessments
were performed at baseline and at 6 months from the first
questionnaire date. The baseline survey was done during
hospitalization; however, the patients were asked about
their pre-morbid condition before acute illness. After in-
formed consent was obtained, study coordinators decided
whether the patient was competent enough to inde-
pendently complete the questionnaire by performing the
mini-mental status examination (MMSE). If the patient
was deemed incompetent (abnormal MMSE) or too ill to
complete the survey (unable to speak due to critical ill-
ness), a surrogate was acknowledged to help answer the
questions on behalf of the patient. Follow-up contact
information was attained, and the patients or their surro-
gates who successfully completed the baseline survey were
contacted by the center personnel by telephone 6 months
after that hospitalization. The pre-specified primary end-
point was the change at 6 months from baseline in QOL
and functional status. QOL and functional status mea-
sures were then compared between patients who did and
did not develop ARDS.
Statistical analysis
The SF-12 was scored according to the normative stan-
dards established by Ware et al. [21], such that persons
with a normal health-related quality of life (HRQOL)
would have an average SF-12 score of 50, with a standard
deviation (SD) of 10. Scores <50 indicate a poor HRQOL,
while scores >50 indicate a better HRQOL. The SF-12 is
standardized to the US population and it is described in
means and SD. Categorical variables are presented as
counts and percentages. Continuous data are summarized
as means (SD) or medians (25 − 75 % interquartile range
(IQR)). The paired t test was used to assess change (delta)
in patients’ SF-12 scores between baseline and 6-month
follow up (within patient change). The independent t test
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was used to compare the mean baseline, 6-month, and
delta (6 months – baseline) SF-12 scores between ARDS
and non-ARDS groups. The Wilcoxon signed rank test
was used to assess change (delta) in patients’ BI scores
between baseline and 6-month follow up (within patient
change); and the Wilcoxon rank sum test was used to
compare the BI in the two groups. Non-parametric tests
were used for analysis of BI scores, because the data distri-
bution was skewed. Butterfly (stream) plots were used to
illustrate the trajectory of each patient’s functional status
and QOL from baseline to 6 months.
A comparison of QOL was made between our study
population and the general US population. The t test
was used to evaluate whether our population mean SF-12
score was different from 50, which is the population norm
[25]. Analysis of covariance was performed to evaluate
ARDS as a predictor of the main outcomes (SF-12 and BI
scores), after adjusting for age, sex and baseline values of
SF-12 and BI scores. Additional sensitivity analysis was
performed to address the survival bias where enrolled pa-
tients who died before their 6 months assessment were
given the lowest possible scores (zero) for SF-12 and BI. A
sensitivity analysis limited to self-answered surveys was
used to address the potential bias, given the different per-
centage in survey response by the patients. The traditional
p value cutoff ≤0.05 was used for statistical significance.
Statistical analyses were performed using SAS (version
9.1, SAS Institute, Cary, NC, USA). Statistical graphs were
developed using the R statistical software functions [26].
Results
Of 410 patients who were identified with ARDS or at
risk of ARDS at the time of hospital admission during
the 3-year study period (2008 − 2011), 98 had baseline
surveys collected (Consolidated Standards of Reporting
Trials (CONSORT) flowchart diagram, Fig. 1). Eligible
patients who did and did not complete the baseline survey
had similar sex, race, ARDS status and Charlson comorbid-
ity index (Additional file 1: Online Resource 1). Patients
who did not complete the baseline survey were older (67
vs. 62 years), had a higher APACHE III score (80 vs. 71),
were more often treated in the ICU (68 vs. 54 %), and had
higher mortality (Additional file 1: Online Resource 1).
Of the 98 enrolled patients, 25 died, 3 refused to
continue in the study, 3 were lost to follow up, and 67
survivors (92 % of those eligible) responded to a 6-month
follow-up survey (26 patients with ARDS and 41 without)
(Fig. 1). Baseline characteristics were similar between the
groups with and without ARDS (Table 1). The ARDS pa-
tients had more days of invasive mechanical ventilation
compared to non-ARDS patients, and longer ICU and
hospital length of stay (Table 1).
Baseline surveys were self-answered by 75 % of the
patients in the non-ARDS group, and by 54 % of the
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart diagram. ARDS acute respiratory distress syndrome
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patients in the ARDS group (p = 0.02). Six-month surveys
were self-answered by 83 % of the patients in the non-
ARDS group, and by 85 % of the patients in the ARDS
group (p = 0.86).
Quality of life
Mental component score of SF-12
There was no within-patient difference in the mental
component score 6 months post baseline, either in the
ARDS (49.7 at baseline vs. 46.9 at 6 months) or in the
non-ARDS groups (51.3 vs. 48.9) (Table 2). There was
also no difference in the mental component of SF-12 at
baseline or at 6 months between patients with and with-
out ARDS. Furthermore, there was no difference when
we compared the change in mental component score
(delta 6 months – baseline) between the two groups
(Table 2 and Fig. 2). Overall the baseline mental compo-
nent scores of SF-12 in both groups were comparable to
the healthy population (SF-12 score of 50).
Physical component score of the SF-12
Both the ARDS and non-ARDS groups had a lower
physical component score of the SF-12 at baseline and
at 6 months compared to the mean score of the general
US population (ARDS group vs. general population at
baseline, p <0.0001, and at 6 months, p <0.0001; non-
ARDS group vs. general population at baseline, p = 0.0001,
and at 6 months, p <0.0001).
As with the mental health score of the SF-12, there
were no within-patient differences in either the ARDS or
the non-ARDS group in the physical component score
6 months from baseline (ARDS group 32.8 at baseline
vs. 35.7 at 6 months; non-ARDS group 37.8 vs. 41.1)
(Table 2). There was also no difference at baseline or at
6 months in the physical component score between the
ARDS and non-ARDS groups. Additionally, no differ-
ence was elicited when we compared the change in the
physical component score (delta 6 months – baseline)
between the two groups (Table 2 and Fig. 2).
Functional status
The ARDS group had a significantly lower mean BI
score at baseline and at 6 months compared to the non-
ARDS group (Table 3). These scores indicate that ARDS
patients had a deficit in their activities of daily living
even before hospital admission. There was no within-
Table 1 Characteristics of 6-month survivors with and without ARDS
ARDS (n = 26) Non-ARDS (n = 41) P value
Age, median (IQR) 60.6 (50.6, 69.0) 59.4 (44.0, 70.9) 0.9a
Female sex, number (%) 13 (50) 20 (49) 0.9b
White race, number (%) 18 (69) 33 (80) 0.4b
ICU admission, number (%) 26 (100) 27 (66) 0.1a
Apache III 24 hours, median (IQR) 68.5 (53, 91.3) 71 (51, 79) 0.7a
Invasive mechanical ventilation, number (%) 23 (88) 14 (34) <0.001b
Invasive MV days, median (IQR) 3.0 (0.3, 11.0) 0 (0, 2.0) 0.005a
ICU LOS, median (IQR) 7.9 (4.1, 18.1) 3.1 (1.1, 7.2) 0.005a
Hospital LOS, median (IQR) 19.5 (11.1, 32.6) 10.6 (6.1, 14.1) 0.004a
Self-answered questionnaires at 6-month follow up, number (%) 22 (85) 34 (83) 0.86b
aWilcoxon rank sum test; bChi square test. ARDS acute respiratory distress syndrome; LIPS lung injury prediction score, APACHE acute physiology and chronic health
evaluation; MV mechanical ventilation, LOS length of stay
Table 2 Mental and physical component score of SF-12 at baseline and 6 months among patients with and without ARDS
ARDS (n = 26) Non-ARDS (n = 41) P value for between-patient comparisona
SF-12 MCS baseline - mean ± SD 46.9 ± 12.4 48.9 ± 11.2 0.50
SF-12 MCS 6 months - mean ± SD 49.7 ± 12.2 51.3 ± 10.7 0.56
SF-12 MCS delta (difference in means) 2.7 (95 % CI −5.8, 5.2) 2.4 (95 % CI −5.6, 5.0) 0.9
P value for within-patient comparisonb 0.23 0.13
SF-12 PCS baseline - mean ± SD 35.7 ± 12.7 41.1 ± 13.3 0.11
SF-12 PCS 6 months - mean ± SD 32.8 ± 12.3 37.8 ± 12.3 0.11
SF-12 PCS delta (difference in means) −3 (95 % CI −6.1, 5.5) −3.3 (95 % CI −6.1, 5.4) 0.9
P value for within-patient comparisonb 0.2 0.07
aIndependent t test; bpaired t test. ARDS acute respiratory distress syndrome, MCS mental component score, PCS physical component score, SF-12 12-Item Short
Form Survey
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patient change in BI scores at 6 months compared to
baseline in either group. No difference was found in the
change in BI score (delta 6 months – baseline) between
the two groups.
Butterfly (stream) plots illustrate the trajectory of each
patient’s functional status and QOL, showing no spe-
cific trend in either the ARDS or non-ARDS group
(Additional file 2: Online Resources 2a, b and c).
Analysis of covariance was performed to evaluate
whether ARDS itself was a predictor of QOL and BI at
6 months. After adjusting for age, sex and baseline value
of SF-12 and BI, ARDS was not a statistically significant
predictor of scores for the physical component of the
SF-12 (p = 0.26), the mental component of SF-12 (p = 0.72),
or the BI (p = 0.67).
Post-hoc sensitivity analysis was performed giving the
lowest possible scores (zero) for the SF-12 and BI to the
patients who were enrolled and died before 6-month
follow up. There was no significant difference in the
delta (baseline to 6 months) of SF-12 or BI between
ARDS and non-ARDS groups (Additional file 3: Online
Resource 3 and Additional file 4: Online Resource 4).
Post-hoc sensitivity analysis limited to self-answered
surveys was performed as there was a difference in
survey response (75 % of the non-ARDS group self-
answered the survey, compared to 54 % of the ARDS
group). The sensitivity analysis showed similar results,
with no significant difference in the delta (baseline to
6 months) of the scores for SF-12 or BI between the
ARDS and non-ARDS groups (Additional file 5: Online
Resource 5 and Additional file 6: Online Resource 6).
Discussion
In this prospective, population-based study of patients
at risk of ARDS at the time of hospital admission, we
observed no decline in functional status and QOL at
6 months compared to baseline, in patients who did
and did not develop ARDS. Both groups had a lower
baseline physical component score of the SF-12 com-
pared to the US general population. Patients who de-
veloped ARDS had poor functional status compared
to those who did not, both at baseline and at 6-month
follow up.
An important finding of our study is that patients at
risk of ARDS at hospital admission had significantly
lower baseline QOL than the general population. Al-
though critically ill survivors who developed ARDS re-
quired a longer duration of mechanical ventilation and
ICU stay, they returned to their baseline QOL and func-
tional status to the same extent as patients at risk who
did not develop the syndrome. Previous studies showed
that the post hospitalization QOL of ARDS survivors
was lower than the US general population, especially the
physical component score of SF-36, which is similar to
our results. However, most of these studies did not have
baseline QOL assessed [6, 8–10, 27], demonstrating only
that ARDS survivors had a lower QOL than general
population. Our data suggest that previously reported
decline in QOL and functional status of ARDS survivors
may at least in part be attributed to baseline disability,
rather than being a consequence of critical illness and its
treatment. Using different methodology, Iwashyna et al.
[28] have also pointed out spurious inferences about
long-term outcomes after critical illness, from studies
that do not take into account the baseline status and
trajectories of chronic conditions, particularly in the eld-
erly. These findings may have important implications for
Table 3 BI scores at baseline and 6 months in patients with and without ARDS
ARDS (n = 26) Non-ARDS (n = 41) P value between-patient comparisona
BI baseline, mean ± SD 80.0 ± 24.7 87.8 ± 21.5 0.03
BI 6 months, mean ± SD 82.3 ± 22.9 89.6 ± 23.2 0.007
BI delta (difference in means) 2.3 (95 % CI –3.4, 8.0) 2.0 (95 % CI –3.2, 7.3) 0.5
P value within-patient comparisonb 0.6 0.2
aWilcoxon rank sum test; bWilcoxon signed rank test. ARDS acute respiratory distress syndrome, BI Barthel index
Fig. 2 Mental and physical component scores for the 12-item Short
Form Survey (SF-12) measured at baseline and 6 months in patients
with acute respiratory distress syndrome (ARDS) and patients without
ARDS (non-ARDS). MCS mental component score, PCS physical
component score
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designing the best strategies for treatment and pre-
vention of long-term disability in survivors of critical
illness.
In this study, patients who survived critical illness,
regardless of whether they developed ARDS or not,
returned to their pre-morbid QOL and functional status
by 6 months. A few other studies with baseline assess-
ment in a general ICU population have found similar
results [29–35]. They found that QOL assessed many
months after ICU discharge through the SF-36 in five of
these studies [30–34] and through the Karnofsky per-
formance status scores in one study [29], either returned
to the baseline value or improved over time. Recently, a
secondary analysis in a multicenter study have found
pre-hospitalization QOL to be the main determinant of
post-discharge QOL with minimal decrement due to
hospitalization that was similar in ICU and non-ICU
patients [36]. Functional decline attributed to critical
illness noted in some of the previous studies [37, 38]
may be related to different patient populations, different
practice patterns and the timing of the assessment of
baseline functional status.
An important difference between our study and the
previous studies that prospectively evaluated QOL in
ARDS survivors [6, 8] is the larger potential for selec-
tion bias inherent in clinical trials or referral center
studies compared to population-based studies. For ex-
ample, the average age of patients in our population-
based study was much older than in the previous
studies [6, 8]. Moreover, the former two studies were
done almost ten years before our study, so changes in
medical practice could have accounted for some of
the discrepancies.
The main strengths of our study include the assess-
ment of the baseline condition of the subjects and the
comparison with a control group of patients at risk of
ARDS who did not develop the syndrome. Very few
studies have a control group of patients who are also
critically ill but do not have ARDS [11, 39–41]. With the
exception of one study [11], the other three studies
[39–41] showed there was no significant difference in
long-term QOL between patients with ARDS and crit-
ically ill patients without ARDS.
Our study has several limitations, starting with re-
cruitment difficulties secondary to the decrease in
ARDS incidence in Olmsted County, Minnesota [42],
our sample size was smaller than intended; this not
only affected the power of the study, but also it lim-
ited our ability to adjust for additional confounders.
The study was stopped when preliminary analyses
after three years showed a decreasing number of
ARDS cases and no trend towards clinically signifi-
cant differences between patients at risk who did and
did not develop the syndrome. Therefore, the study
was underpowered to evaluate small differences in
QOL and functional status. However, clinically im-
portant differences are not likely to be missed as the
effect sizes within groups and between groups were
smaller than the minimal clinically important differ-
ence (MCID) of the SF-12 (0.5 of the SD = 5 points)
[43]. Estimation of pre-morbid QOL was done by sur-
rogates rather than patients in a significant number
of ARDS patients, potentially affecting the accuracy of
baseline QOL assessment [44].
Although population-based studies tend to have less
selection bias than studies that follow patients from clin-
ical trials, only 25 % of eligible patients at risk had base-
line surveys completed in our study (Fig. 1), raising the
issue of informative censoring. Although patients who
were eligible but not enrolled had similar ARDS status
and Charlson comorbidity index, they were older, more
often treated in the ICU, had higher APACHE III score
and had higher mortality than those enrolled. A number
of patients who refused to participate did so due to
change in goals of care which indeed might reflect poor
prognosis. Also, some patients who completed the base-
line survey died prior to completion of the follow-up
survey at 6 months. This might represent a survival bias;
however, this has been an issue throughout the studies
involving long-term outcomes of critically ill patients.
To address this issue, a post-hoc sensitivity analysis was
performed and there was no significant difference be-
tween the two groups in the delta (baseline to 6 months)
of SF-12 and BI scores. Finally, this is a single-center
investigation with a largely Caucasian population, which
limits the generalizability.
Conclusions
In this prospective population-based study, survivors
who did and did not develop ARDS returned to base-
line QOL and functional status 6 months after hos-
pitalization, though the physical component score of
SF-12 remained lower than the average general US
population in both groups. Our study results suggest
that lower QOL and functional status after hospi-
talization were largely explained by baseline conditions,
with similar recovery in survivors who did and did not
develop ARDS.
Key message
 In this prospective, population-based study of
patients at risk of ARDS at the time of hospital
admission, decreased quality of life and functional
status 6 months after hospitalization were largely
explained by their baseline condition, with
similar recovery in survivors who did and did not
develop ARDS
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